International Journal of Hematology

, Volume 77, Issue 3, pp 286–294 | Cite as

The Serum Cytokine Profiles of Lymphoma-associated Hemophagocytic Syndrome: A Comparative Analysis of B-Cell and T-Cell/Natural Killer Cell Lymphomas

  • Tatsuharu Ohno
  • Yasunori Ueda
  • Ken-ichi Nagai
  • Takayuki Takahashi
  • Yoshiteru Konaka
  • Teruyuki Takamatsu
  • Takayo Suzuki
  • Masataka Sasada
  • Takashi Uchiyama


To elucidate the differences in pathogenesis between lymphoma-associated hemophagocytic syndromes (LAHS) of theT-cell/ natural killer cell (T/NK) and B-cell (B) types,we comparatively analyzed the clinical features and serum cytokine profiles of 33 patients with LAHS registered in the Kyoto University Hematology/Oncology Study Group.The serum cytokine levels of each patient group (B-LAHS versusT/NK-LAHS) were expressed as the ratio of the median to the upper normal values of the respective cytokines and were as follows: 19.05 versus 13.99 for soluble interleukin 2 (IL-2) receptor, 0.67 versus 0.67 for granulocytemacrophage colony-stimulating factor (GM-CSF), 0.64 versus 1.26 for G-CSF, 5.70 versus 3.61 for M-CSF, 1.54 versus 3.39 for interferon γ (IFN-γ), 13.17 versus 1.17 for IL-6, 6.88 versus 1.58 for tumor necrosis factor α (TNF-α), 0.71 versus 0.41 for IL-1, 1.99 versus 0.21 for IL-12, and 105.32 versus 29.65 for IL-10.The serum levels of IL-6,TNF-α, and IL-10 were significantly higher in the B-LAHS group,whereas those of IFN-γ were significantly lower. These differences between the 2 groups may reflect a difference in the pathogenesis. Higher serum levels of IL-6, TNF-α, and IL-10 may be derived at least partly from neoplastic B-cells themselves. In addition, the extremely high serum levels of IL-10 suggest that a compensatory anti-inflammatory process may operate in both groups and give rise to a profound immunosuppressive state and a poor outcome.

Key words

Malignant lymphoma Hemophagocytic syndrome Cytokine Intravascular lymphomatosis Systemic inflammatory response syndrome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wong KF, Chan JK. Reactive hemophagocytic syndrome: a clinicopathologic study of 40 patients in an Oriental population.Am J Med. 1992;93:177–180.CrossRefPubMedGoogle Scholar
  2. 2.
    Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment.Int J Hematol. 1997;66:135–151.CrossRefPubMedGoogle Scholar
  3. 3.
    Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes.Blood. 1989;73:2128–2132.PubMedGoogle Scholar
  4. 4.
    Ishii E, Ohga S, Aoki T, et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor.Acta Haematol. 1991;85:93–99.CrossRefPubMedGoogle Scholar
  5. 5.
    Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels of interferon-gamma, cytotoxic factor and soluble interleukin-2 receptor in childhood hemophagocytic syndromes.Leuk Lymphoma. 1991;3:287–292.CrossRefPubMedGoogle Scholar
  6. 6.
    Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome.Am J Pediatr Hematol Oncol. 1993;15:92–98.CrossRefPubMedGoogle Scholar
  7. 7.
    Akashi K, Hayashi S, Gondo H, et al. Involvement of interferon- and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults.Br J Haematol. 1994;87:243–250.CrossRefPubMedGoogle Scholar
  8. 8.
    Imashuku S, Hibi S, Fujiwara F, Ikushima S, Todo S. Haemophagocytic lymphohistiocytosis, interferon-gamma-naemia and Epstein- Barr virus involvement.Br J Haematol. 1994;88:656–658.CrossRefPubMedGoogle Scholar
  9. 9.
    Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.J Clin Oncol. 1995;13:575–582.CrossRefPubMedGoogle Scholar
  10. 10.
    Imashuku S, Hibi S, Fujiwara F, Toda S. Hyper-interleukin (IL)-6- naemia in haemophagocytic lymphohistiocytosis.Br J Haematol. 1996;93:803–807.CrossRefPubMedGoogle Scholar
  11. 11.
    Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis.Blood. 1997;89:4100–4103.PubMedGoogle Scholar
  12. 12.
    Takada H, Ohga S, Mizuno Y, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity.Br J Haematol. 1999;106:182–189.CrossRefPubMedGoogle Scholar
  13. 13.
    Takeshita M, Kikuchi M, Ohshima K, et al. Bone marrow findings in malignant histiocytosis and/or malignant lymphoma with concurrent hemophagocytic syndrome.Leuk Lymphoma. 1993;12:79–899.CrossRefPubMedGoogle Scholar
  14. 14.
    Yao M, Cheng AL, Su IJ, et al. Clinicopathological spectrum of hemophagocytic syndrome in Epstein-Barr virus-associated peripheral T cell lymphoma.Br J Haematol. 1994;87:535–543.CrossRefPubMedGoogle Scholar
  15. 15.
    Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA. Malignant histiocytosis: a reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies.Cancer. 1990;66:530–536.CrossRefPubMedGoogle Scholar
  16. 16.
    Reiner AP, Spivak JL. Hematophagic histiocytosis: a report of 23 new patients and a review of the literature.Medicine. 1988;67:369–3888.CrossRefPubMedGoogle Scholar
  17. 17.
    Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome.Blood. 1990;75:434–444.PubMedGoogle Scholar
  18. 18.
    Cheng AL, Su IJ, Chen YC, Uen WC, Wang CH. Characteristic clinicopathological features of Epstein-Barr virus-associated peripheral T-cell lymphoma.Cancer. 1993;72:909–916.CrossRefPubMedGoogle Scholar
  19. 19.
    Chang CS, Wang CH, Su IJ, Chen YC, Shen MC. Hematophagic histiocytosis: a clinicopathologic analysis of 23 cases with special reference to the association with peripheral T-cell lymphoma.J Formos Med Assoc. 1994;93:421–428.PubMedGoogle Scholar
  20. 20.
    Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.Leuk Lymphoma. 1995;19:401–406.CrossRefPubMedGoogle Scholar
  21. 21.
    Wong KF, Chan JKC, Lo ESF, Wong CSC. A study of the possible etiologic association of Epstein-Barr virus with reactive hemophagocytic syndrome in Hong Kong Chinese.Hum Pathol. 1996;27:1239–12422.CrossRefPubMedGoogle Scholar
  22. 22.
    Kuratsune H, Machii T, Aozaka K, et al. B cell lymphoma showing clinicopathological features of malignant histiocytosis.Acta Haematol. 1988;79:94–98.CrossRefPubMedGoogle Scholar
  23. 23.
    Nakamoto T, Ogawa S, Mano H, Hirai H, Yazaki Y. Hemophagocytic syndrome associated with non-Hodgkin’s lymphoma of B-cell type.Am J Hematol. 1994;47:335–336.CrossRefPubMedGoogle Scholar
  24. 24.
    Murase T, Nakamura S, Tashiro K, et al. Malignant histiocytosislike B-cell lymphoma, a distinct variant of intravascular lymphomatosis: a report of five cases and review of the literature.Br J Haematol. 1997;99:656–664.CrossRefPubMedGoogle Scholar
  25. 25.
    Ohno T, Miyake N, Hada S, et al. Hemophagocytic syndrome in five patients with Epstein-Barr virus-negative B-cell lymphoma.Cancer. 1998;82:1963–1972.CrossRefPubMedGoogle Scholar
  26. 26.
    Takahashi T, Kanda Y, Mori M, et al. B-cell lymphoma-associated hemophagocytic syndrome after PBSCT.Bone Marrow Transplant. 1998;21:623–625.CrossRefPubMedGoogle Scholar
  27. 27.
    Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study.Br J Haematol. 1999;104:672–679.CrossRefPubMedGoogle Scholar
  28. 28.
    Takahashi N, Chubati A, Miura I, Nakamura S, Miura T. Lymphoma- associated hemophagocytic syndrome in Japan [in Japanese, abstract in English].Jpn J Clin Hematol. 1999;40:542–549.Google Scholar
  29. 29.
    Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics.Ann Hematol. 2000;79:378–388.CrossRefPubMedGoogle Scholar
  30. 30.
    Allory Y, Challine D, Haioun C, et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution.Am J Surg Pathol. 2001;25:865–874.CrossRefPubMedGoogle Scholar
  31. 31.
    Su IJ, Hsieh HC, Lin KH, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis.Blood. 1991;77:799–808.PubMedGoogle Scholar
  32. 32.
    Craig FE, Clare CN, Sklar JL, Banks PM. T-cell lymphoma and the virus-associated hemophagocytic syndrome.Am J Clin Pathol. 1992;97:189–194.CrossRefPubMedGoogle Scholar
  33. 33.
    Kikuta H, Sakiyama Y, Matsumoto S, et al. Fatal Epstein-Barr virus-associated hemophagocytic syndrome.Blood. 1993;82:3259–32644.PubMedGoogle Scholar
  34. 34.
    Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virusinfected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome.J Clin Invest. 1993;92:1444–1450.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Su IJ, Hsu YH, Lin MT, Cheng AL, Wang CH, Weiss LM. Epstein- Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis.Cancer. 1993;72:2019–20277.CrossRefPubMedGoogle Scholar
  36. 36.
    Dolezal MV, Kamel OW, van de Rijin M, Cleary ML, Sibley RK, Warnke RA. Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome.Am J Clin Pathol. 1995;103:189–194.CrossRefPubMedGoogle Scholar
  37. 37.
    Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.J Clin Invest. 1997;100:1969–19799.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ohshima K, Haraoka S, Harada N, et al. Hepatosplenic gamma delta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules.Histopathology. 2000;36:127–135.CrossRefPubMedGoogle Scholar
  39. 39.
    Ohno T, Kanoh T, Arita Y, et al. Fulminant clonal expansion of large granular lymphocytes: characterization of their morphology, phenotype, genotype, and function.Cancer. 1988;62:1918–1927.CrossRefPubMedGoogle Scholar
  40. 40.
    Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein- Barr viral DNA.J Clin Invest. 1989;84:51–55.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colonystimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay.Blood. 1989;73:117–122.PubMedGoogle Scholar
  42. 42.
    Heaney ML, Dolde DW. Soluble cytokine receptors.Blood. 1996; 87:847–857.PubMedGoogle Scholar
  43. 43.
    Luoghnan MS, Sanderson CJ, Nossal GJV. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5.Proc Natl Acad Sci U S A. 1988;85:3115–3119.CrossRefGoogle Scholar
  44. 44.
    de Totero D, di Celle PF, Cignetti A, Foa R. The IL-2 receptor complex: expression and function on normal and leukemic B cells.Leukemia. 1995;9:1425–1431.PubMedGoogle Scholar
  45. 45.
    Imashuku S, Hibi S, Tabata Y, Todo S. Hemophagocytic syndrome in five patients with Epstein-Barr virus-negative B-cell lymphoma.Cancer. 1999;85:2298–2300.CrossRefPubMedGoogle Scholar
  46. 46.
    Abken H, Fluck J, Willecke J. Four cell-secreted cytokines act synergistically to maintain long term proliferation of human B cell lines in vitro.J Immunol. 1992;149:2785–2794.PubMedGoogle Scholar
  47. 47.
    Boussiotis VA, Nadler LM, Strominger JL, Goldfeld E. Tumor necrosis factor is an autocrine growth factor for normal human B cells.Proc Natl Acad Sci U S A. 1994;91:7007–7011.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Genestier L, Bonnefoy-Berard N, Rouault JP, Flacher M, Revillard JP. Tumor necrosis factor-up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines.Int Immunol. 1995;7:533–540.CrossRefPubMedGoogle Scholar
  49. 49.
    Kato H, Kinoshita T, Suzuki S, et al. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with Bcell non-Hodgkin’s lymphoma: correlation with extent of IL-6 expression and serum concentration.Br J Haematol. 1996;92:1014–10211.CrossRefPubMedGoogle Scholar
  50. 50.
    Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors.Cancer Res. 1996;56:5499–5505.PubMedGoogle Scholar
  51. 51.
    Benjamin D, Park CD, Sharma V. Human B cell interleukin 10.Leuk Lymphoma. 1994;12:205–210.CrossRefPubMedGoogle Scholar
  52. 52.
    Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin’s lymphoma.Leuk Lymphoma. 1997;26:251–259.CrossRefPubMedGoogle Scholar
  53. 53.
    Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies.Cancer Immunol Immunother. 1998;46:239–244.CrossRefPubMedGoogle Scholar
  54. 54.
    Ip M, Chan KW, Chan IKL. Systemic inflammatory response syndrome in intravascular lymphomatosis.Intensive Care Med. 1997; 23:783–786.CrossRefPubMedGoogle Scholar
  55. 55.
    Deusch E, Mayer A, Hobisch-Hagen P, et al. Angiotropic large Bcell lymphoma misdiagnosed as urosepsis with multiple organ dysfunction syndrome.Acta Anaesthesiol Scand. 1999;43:100–103.CrossRefPubMedGoogle Scholar
  56. 56.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med. 1992;20:864–874.CrossRefGoogle Scholar
  57. 57.
    Romagnani S. Cytokines and the Th1/Th2 paradigm. In: Balkwill F, ed. The Cytokine Network and Immune Functions. Oxford, UK: Oxford University Press; 2000:73–93.Google Scholar
  58. 58.
    Kallio R, Surcel HM, Bloigu A, Syrjala A. Balance between interleukin- 10 and interleukin-12 in adult cancer patients with or without infections.Eur J Cancer. 2001;37:857–861.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Tatsuharu Ohno
    • 1
  • Yasunori Ueda
    • 2
  • Ken-ichi Nagai
    • 3
  • Takayuki Takahashi
    • 3
  • Yoshiteru Konaka
    • 4
  • Teruyuki Takamatsu
    • 5
  • Takayo Suzuki
    • 6
  • Masataka Sasada
    • 7
  • Takashi Uchiyama
    • 8
  1. 1.Division of Hematology and Immunology, Department of Internal MedicineOhtsu Red Cross HospitalOhtsuJapan
  2. 2.Department of Hematology and OncologyKurashiki Central HospitalKurashiki
  3. 3.Department of Hematology and ImmunologyKobe Central Municipal HospitalKobe
  4. 4.Division of Hematology and Rheumatology, Department of MedicineKitano HospitalOsaka
  5. 5.Department of Hematology and ImmunologyRakuwakai Otowa HospitalKyoto
  6. 6.Department of HematologyShiga Prefectural Center for Adult DiseaseMoriyama
  7. 7.College of Medical TechnologyKyoto UniversityKyoto
  8. 8.Department of Hematology/Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations